353 related articles for article (PubMed ID: 21124768)
21. A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants.
; Agnandji ST; Lell B; Fernandes JF; Abossolo BP; Methogo BG; Kabwende AL; Adegnika AA; Mordmüller B; Issifou S; Kremsner PG; Sacarlal J; Aide P; Lanaspa M; Aponte JJ; Machevo S; Acacio S; Bulo H; Sigauque B; Macete E; Alonso P; Abdulla S; Salim N; Minja R; Mpina M; Ahmed S; Ali AM; Mtoro AT; Hamad AS; Mutani P; Tanner M; Tinto H; D'Alessandro U; Sorgho H; Valea I; Bihoun B; Guiraud I; Kaboré B; Sombié O; Guiguemdé RT; Ouédraogo JB; Hamel MJ; Kariuki S; Oneko M; Odero C; Otieno K; Awino N; McMorrow M; Muturi-Kioi V; Laserson KF; Slutsker L; Otieno W; Otieno L; Otsyula N; Gondi S; Otieno A; Owira V; Oguk E; Odongo G; Woods JB; Ogutu B; Njuguna P; Chilengi R; Akoo P; Kerubo C; Maingi C; Lang T; Olotu A; Bejon P; Marsh K; Mwambingu G; Owusu-Agyei S; Asante KP; Osei-Kwakye K; Boahen O; Dosoo D; Asante I; Adjei G; Kwara E; Chandramohan D; Greenwood B; Lusingu J; Gesase S; Malabeja A; Abdul O; Mahende C; Liheluka E; Malle L; Lemnge M; Theander TG; Drakeley C; Ansong D; Agbenyega T; Adjei S; Boateng HO; Rettig T; Bawa J; Sylverken J; Sambian D; Sarfo A; Agyekum A; Martinson F; Hoffman I; Mvalo T; Kamthunzi P; Nkomo R; Tembo T; Tegha G; Tsidya M; Kilembe J; Chawinga C; Ballou WR; Cohen J; Guerra Y; Jongert E; Lapierre D; Leach A; Lievens M; Ofori-Anyinam O; Olivier A; Vekemans J; Carter T; Kaslow D; Leboulleux D; Loucq C; Radford A; Savarese B; Schellenberg D; Sillman M; Vansadia P
N Engl J Med; 2012 Dec; 367(24):2284-95. PubMed ID: 23136909
[TBL] [Abstract][Full Text] [Related]
22. A randomized trial assessing the safety and immunogenicity of AS01 and AS02 adjuvanted RTS,S malaria vaccine candidates in children in Gabon.
Lell B; Agnandji S; von Glasenapp I; Haertle S; Oyakhiromen S; Issifou S; Vekemans J; Leach A; Lievens M; Dubois MC; Demoitie MA; Carter T; Villafana T; Ballou WR; Cohen J; Kremsner PG
PLoS One; 2009 Oct; 4(10):e7611. PubMed ID: 19859560
[TBL] [Abstract][Full Text] [Related]
23. Five-year safety and immunogenicity of GlaxoSmithKline's candidate malaria vaccine RTS,S/AS02 following administration to semi-immune adult men living in a malaria-endemic region of The Gambia.
Bojang K; Milligan P; Pinder M; Doherty T; Leach A; Ofori-Anyinam O; Lievens M; Kester K; Schaecher K; Ballou WR; Cohen J
Hum Vaccin; 2009 Apr; 5(4):242-7. PubMed ID: 19276646
[TBL] [Abstract][Full Text] [Related]
24. Immune response to the hepatitis B antigen in the RTS,S/AS01 malaria vaccine, and co-administration with pneumococcal conjugate and rotavirus vaccines in African children: A randomized controlled trial.
Valéa I; Adjei S; Usuf E; Traore O; Ansong D; Tinto H; Owusu Boateng H; Leach A; Mwinessobaonfou Some A; Buabeng P; Vekemans J; Nana LA; Kotey A; Vandoolaeghe P; Ouedraogo F; Sambian D; Lievens M; Tahita MC; Rettig T; Jongert E; Lompo P; Idriss A; Borys D; Ouedraogo S; Prempeh F; Habib MA; Schuerman L; Sorgho H; Agbenyega T
Hum Vaccin Immunother; 2018 Jun; 14(6):1489-1500. PubMed ID: 29630438
[TBL] [Abstract][Full Text] [Related]
25. Satisfactory safety and immunogenicity of MSP3 malaria vaccine candidate in Tanzanian children aged 12-24 months.
Lusingu JP; Gesase S; Msham S; Francis F; Lemnge M; Seth M; Sembuche S; Rutta A; Minja D; Segeja MD; Bosomprah S; Cousens S; Noor R; Chilengi R; Druilhe P
Malar J; 2009 Jul; 8():163. PubMed ID: 19607731
[TBL] [Abstract][Full Text] [Related]
26. Environmental modifiers of RTS,S/AS01 malaria vaccine efficacy in Lilongwe, Malawi.
Bell GJ; Loop MS; Mvalo T; Juliano JJ; Mofolo I; Kamthunzi P; Tegha G; Lievens M; Bailey J; Emch M; Hoffman I
BMC Public Health; 2020 Jun; 20(1):910. PubMed ID: 32532234
[TBL] [Abstract][Full Text] [Related]
27. Effect of ingested human antibodies induced by RTS, S/AS01 malaria vaccination in children on Plasmodium falciparum oocyst formation and sporogony in mosquitoes.
Miura K; Jongert E; Deng B; Zhou L; Lusingu JP; Drakeley CJ; Fay MP; Long CA; Vekemans J
Malar J; 2014 Jul; 13():263. PubMed ID: 25007730
[TBL] [Abstract][Full Text] [Related]
28. Safety, immunogenicity and duration of protection of the RTS,S/AS02(D) malaria vaccine: one year follow-up of a randomized controlled phase I/IIb trial.
Aide P; Aponte JJ; Renom M; Nhampossa T; Sacarlal J; Mandomando I; Bassat Q; Manaca MN; Leach A; Lievens M; Vekemans J; Dubois MC; Loucq C; Ballou WR; Cohen J; Alonso PL
PLoS One; 2010 Nov; 5(11):e13838. PubMed ID: 21079803
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of the immune response to RTS,S/AS01 and RTS,S/AS02 adjuvanted vaccines: randomized, double-blind study in malaria-naïve adults.
Leroux-Roels G; Leroux-Roels I; Clement F; Ofori-Anyinam O; Lievens M; Jongert E; Moris P; Ballou WR; Cohen J
Hum Vaccin Immunother; 2014; 10(8):2211-9. PubMed ID: 25424924
[TBL] [Abstract][Full Text] [Related]
30. Feasibility, safety, and impact of the RTS,S/AS01
Asante KP; Mathanga DP; Milligan P; Akech S; Oduro A; Mwapasa V; Moore KA; Kwambai TK; Hamel MJ; Gyan T; Westercamp N; Kapito-Tembo A; Njuguna P; Ansong D; Kariuki S; Mvalo T; Snell P; Schellenberg D; Welega P; Otieno L; Chimala A; Afari EA; Bejon P; Maleta K; Agbenyega T; Snow RW; Zulu M; Chinkhumba J; Samuels AM;
Lancet; 2024 Apr; 403(10437):1660-1670. PubMed ID: 38583454
[TBL] [Abstract][Full Text] [Related]
31. Transcriptional correlates of malaria in RTS,S/AS01-vaccinated African children: a matched case-control study.
Moncunill G; Carnes J; Chad Young W; Carpp L; De Rosa S; Campo JJ; Nhabomba A; Mpina M; Jairoce C; Finak G; Haas P; Muriel C; Van P; Sanz H; Dutta S; Mordmüller B; Agnandji ST; Díez-Padrisa N; Williams NA; Aponte JJ; Valim C; Neafsey DE; Daubenberger C; McElrath MJ; Dobaño C; Stuart K; Gottardo R
Elife; 2022 Jan; 11():. PubMed ID: 35060479
[TBL] [Abstract][Full Text] [Related]
32. Safety and immunogenicity of the RTS,S/AS02A candidate malaria vaccine in children aged 1-4 in Mozambique.
Macete E; Aponte JJ; Guinovart C; Sacarlal J; Ofori-Anyinam O; Mandomando I; Espasa M; Bevilacqua C; Leach A; Dubois MC; Heppner DG; Tello L; Milman J; Cohen J; Dubovsky F; Tornieporth N; Thompson R; Alonso PL
Trop Med Int Health; 2007 Jan; 12(1):37-46. PubMed ID: 17207146
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of RTS,S/AS02A and RTS,S/AS01B in adults in a high malaria transmission area.
Polhemus ME; Remich SA; Ogutu BR; Waitumbi JN; Otieno L; Apollo S; Cummings JF; Kester KE; Ockenhouse CF; Stewart A; Ofori-Anyinam O; Ramboer I; Cahill CP; Lievens M; Dubois MC; Demoitie MA; Leach A; Cohen J; Ballou WR; Heppner DG
PLoS One; 2009 Jul; 4(7):e6465. PubMed ID: 19649245
[TBL] [Abstract][Full Text] [Related]
34. CNS infection safety signal of RTS,S/AS01 and possible association with rabies vaccine.
Gessner BD; Wraith DC; Finn A
Lancet; 2016 Apr; 387(10026):1376. PubMed ID: 27115819
[No Abstract] [Full Text] [Related]
35. A Phase IIa Controlled Human Malaria Infection and Immunogenicity Study of RTS,S/AS01E and RTS,S/AS01B Delayed Fractional Dose Regimens in Malaria-Naive Adults.
Moon JE; Ockenhouse C; Regules JA; Vekemans J; Lee C; Chuang I; Traskine M; Jongert E; Ivinson K; Morelle D; Komisar JL; Lievens M; Sedegah M; Garver LS; Sikaffy AK; Waters NC; Ballou WR; Ofori-Anyinam O;
J Infect Dis; 2020 Oct; 222(10):1681-1691. PubMed ID: 32687161
[TBL] [Abstract][Full Text] [Related]
36. Immunogenicity and safety of the candidate RTS,S/AS01 vaccine in young Nigerian children: a randomized, double-blind, lot-to-lot consistency trial.
Umeh R; Oguche S; Oguonu T; Pitmang S; Shu E; Onyia JT; Daniyam CA; Shwe D; Ahmad A; Jongert E; Catteau G; Lievens M; Ofori-Anyinam O; Leach A
Vaccine; 2014 Nov; 32(48):6556-62. PubMed ID: 25077418
[TBL] [Abstract][Full Text] [Related]
37. Could the RTS,S/AS01 meningitis safety signal really be a protective effect of rabies vaccine?
Gessner BD; Knobel DL; Conan A; Finn A
Vaccine; 2017 Feb; 35(5):716-721. PubMed ID: 28065475
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial.
Datoo MS; Natama MH; Somé A; Traoré O; Rouamba T; Bellamy D; Yameogo P; Valia D; Tegneri M; Ouedraogo F; Soma R; Sawadogo S; Sorgho F; Derra K; Rouamba E; Orindi B; Ramos Lopez F; Flaxman A; Cappuccini F; Kailath R; Elias S; Mukhopadhyay E; Noe A; Cairns M; Lawrie A; Roberts R; Valéa I; Sorgho H; Williams N; Glenn G; Fries L; Reimer J; Ewer KJ; Shaligram U; Hill AVS; Tinto H
Lancet; 2021 May; 397(10287):1809-1818. PubMed ID: 33964223
[TBL] [Abstract][Full Text] [Related]
39. Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants.
Abdulla S; Oberholzer R; Juma O; Kubhoja S; Machera F; Membi C; Omari S; Urassa A; Mshinda H; Jumanne A; Salim N; Shomari M; Aebi T; Schellenberg DM; Carter T; Villafana T; Demoitié MA; Dubois MC; Leach A; Lievens M; Vekemans J; Cohen J; Ballou WR; Tanner M
N Engl J Med; 2008 Dec; 359(24):2533-44. PubMed ID: 19064623
[TBL] [Abstract][Full Text] [Related]
40. Clinical development of RTS,S/AS malaria vaccine: a systematic review of clinical Phase I-III trials.
Agnandji ST; Fernandes JF; Bache EB; Ramharter M
Future Microbiol; 2015; 10(10):1553-78. PubMed ID: 26437872
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
